Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07256509 | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Dec 5, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 |
| clinicaltrials |
| NCT07235306 | Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC | not yet recruiting | Phase 2 | 45 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07231575 | Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT05393466 | BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 30 | Xcovery Holdings, Inc.INDUSTRY | 0 | Oct 7, 2025 | clinicaltrials |
| NCT07204548 | The IVO-LUNG Study(IVO Lung) | not yet recruiting | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 450 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07193160 | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy | not yet recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 0 | Sep 25, 2025 | clinicaltrials |
| NCT07190027 | Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial | not yet recruiting | Phase 1 / Phase 2 | 246 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT07182708 | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC(HOFIBREN) | not yet recruiting | Phase 2 | 62 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07177092 | Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer(SURGAN-TKI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07177105 | Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC(SURGAN-ICI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07158840 | AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment(AGA TKI NSCLC) | not yet recruiting | Phase 2 | 60 | AkesoINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07156604 | Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153770 | Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07139041 | Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC | not yet recruiting | Phase 2 | 69 | Chang ChenOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT07134413 | QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC | not yet recruiting | Phase 2 | 77 | Guangdong Association of Clinical TrialsOTHER | 0 | Aug 21, 2025 | clinicaltrials |
| NCT07129161 | Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07063329 | Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive | not yet recruiting | Phase 1 / Phase 2 | 108 | Avistone Pharmaceutical（Ningbo）Co., LTD.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07086326 | A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC(NEOINSPIRE) | not yet recruiting | Phase 2 | 164 | Yang Fan, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06951399 | Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07043907 | PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC | not yet recruiting | Phase 2 | 115 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 0 | Jul 1, 2025 | clinicaltrials |
| NCT06977828 | A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07038460 | A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC(NEO-LISI) | not yet recruiting | Phase 2 | 134 | Wen-zhao ZHONGOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07035392 | Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 32 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT07031154 | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07014215 | PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy | not yet recruiting | Phase 2 | 52 | Anhui Provincial Cancer HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07009925 | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | not yet recruiting | Phase 2 | 38 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 8, 2025 | clinicaltrials |
| NCT06998719 | Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC(ACCESS) | not yet recruiting | Phase 2 | 80 | Bi NanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT06962189 | The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study | not yet recruiting | Phase 2 | 39 | Zhejiang UniversityOTHER | 0 | May 8, 2025 | clinicaltrials |
| NCT06946836 | Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study(Neoadjuvant) | not yet recruiting | Phase 2 | 80 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06925048 | SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC | not yet recruiting | Phase 2 | 86 | Chunxia SuOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06908733 | Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC | not yet recruiting | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06890182 | Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | not yet recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06885840 | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. | not yet recruiting | Phase 2 | 100 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06851169 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response | not yet recruiting | Phase 2 | 58 | Tang-Du HospitalOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT06837948 | Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06818955 | Orlistat Overcoming Third-generation EGFR-TKI Resistance(OOTER) | not yet recruiting | Phase 2 | 36 | Ping PengOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06779539 | Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 33 | West China HospitalOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT06780839 | Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD | not yet recruiting | Phase 2 | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06775483 | Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study | not yet recruiting | Phase 2 | 220 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06672068 | A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC | not yet recruiting | Phase 2 | 60 | TYK Medicines, IncINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06752408 | Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer(ANOTHER) | not yet recruiting | Phase 2 | 316 | Peking Union Medical College HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06746870 | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 148 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06690671 | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06644313 | Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 31 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2025source: clinicaltrials